Core Viewpoint - Marker Therapeutics, Inc. is actively participating in the H.C. Wainwright 3 Annual Cell Therapy Virtual Conference to present its advancements in T cell-based immunotherapies for treating hematological malignancies and solid tumors [1][2]. Company Overview - Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company based in Houston, TX, focusing on next-generation T cell-based immunotherapies [4]. - The company was founded at Baylor College of Medicine and has conducted clinical trials involving over 200 patients, demonstrating that its autologous and allogeneic MAR-T cell products are well tolerated and show durable clinical responses [4]. - The company aims to introduce novel T cell therapies to the market while prioritizing financial resource preservation and operational excellence [4]. - Marker Therapeutics benefits from non-dilutive funding from U.S. state and federal agencies that support cancer research [4]. Event Details - Dr. Juan Vera, President and CEO of Marker Therapeutics, will present at the H.C. Wainwright 3 Annual Cell Therapy Virtual Conference on February 25, 2025, at 3:30 PM ET [2][3]. - The event will be held virtually, and registered participants can access the presentation through the event portal [3].
Marker Therapeutics to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference